Sinha Kusum, Sun Chichun, Kamari Rashmi, Bettermann Kerstin
Department of Neurology, Penn State College of Medicine, Hershey, PA, USA.
Department of Neural & Behavioral Sciences, College of Medicine, Hershey, PA, USA.
Drug Discov Today. 2020 Apr;25(4):793-799. doi: 10.1016/j.drudis.2020.01.003. Epub 2020 Jan 22.
Vascular dementia (VaD) is a progressive neurocognitive clinical syndrome that is caused by a decrease in cerebral blood flow and damage to the neurovascular unit. Given increasing life expectancy, VaD is emerging as one of the leading health problems in society. Despite the high global prevalence of cognitive impairment associated with VaD, diagnosis and treatment still remain limited because of the complexity of mechanisms of neuronal loss. Therefore, advances in our understanding of the pathophysiological mechanisms involved is crucial for the development of new therapeutic strategies. In this review, we highlight the pathophysiology, current pharmacology-based primary and secondary prevention strategies and emerging treatment options for VaD.
血管性痴呆（VaD）是一种进行性神经认知临床综合征，由脑血流量减少和神经血管单元受损引起。随着预期寿命的增加，VaD正成为社会上主要的健康问题之一。尽管与VaD相关的认知障碍在全球范围内普遍存在，但由于神经元丢失机制的复杂性，诊断和治疗仍然有限。因此，深入了解其病理生理机制对于开发新的治疗策略至关重要。在这篇综述中，我们重点介绍了VaD的病理生理学、当前基于药理学的一级和二级预防策略以及新兴的治疗选择。
